Selzentry - 2007 FDA approvals

Drug: Selzentry (maraviroc)
Indication: HIV
Company: Pfizer
Approval Date: August 6, 2007

Scoop: Selzentry is a CCR5 antagonist, which prevents the virus from entering white blood cells. The process reduces viral load and boosts T-cell count. For Pfizer, it was a much-needed win on the regulatory side after a series of disappointing setbacks in its pipeline development program.

More news:
Selzentry approval marks big win for Pfizer. Report
Investors yawn at Maraviroc endorsement. Report
New HIV drugs offer breakthrough therapies. Report

Selzentry - 2007 FDA approvals
Read more on

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.